Liver disease in primary antibody deficiencies

Area of Science:

• Immunology
• Hepatology
• Gastroenterology

Background:

• Liver disease is a major cause of mortality in patients with common variable immunodeficiency (CVID).
• Presinusoidal portal hypertension (PHTN), often secondary to nodular regenerative hyperplasia (NRH), is a primary driver of liver-related mortality in CVID.
• The pathogenesis and optimal treatment strategies for CVID-associated liver disease remain incompletely understood.

Purpose of the Study:

• To review recent findings on the pathology, diagnostics, and treatment of liver disease in CVID patients.
• To synthesize current knowledge regarding the pathogenetic sequence leading to PHTN and NRH in CVID.
• To evaluate the efficacy of current treatment modalities, including liver transplantation.

Main Methods:

• Review of recent literature (last 2 years) on CVID-associated liver disease.
• Analysis of histological findings to elucidate pathogenetic mechanisms.
• Evaluation of diagnostic markers and treatment outcomes.

Main Results:

• Histological evidence suggests a T-cell mediated pathway leading to sinusoidal damage, NRH, fibrosis, and PHTN.
• Elevated liver stiffness and splenomegaly (>16 cm) are proposed as potential warning signs for PHTN in CVID.
• Immunosuppressive treatment data is heterogeneous, but liver transplantation shows promise for end-stage liver disease.

Conclusions:

• Liver disease requires greater attention in the clinical management of CVID.
• Further research is essential to elucidate the pathogenesis and establish optimal treatment protocols for CVID-associated liver disease.